Vista Pharmaceuticals share news and announcements
BSE: 524711Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹5.48.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹36 Cr3,508th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 1.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 14 Aug 2026
- −28.7%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 14 Aug 2026
- −32.5%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.27
- Volume, BSEVolume. Shares traded on the last trading day.
- 6,933
Last results date
The last board meeting held for results; the company has not yet given notice of the next.Vista Pharmaceuticals quarterly results
The board met on 14 Aug 2026 to consider quarterly results
Notice filed 13 Aug 2026
Vista Pharmaceuticals annual reports, presentations and earnings calls
The company's own documents, latest first.Vista Pharmaceuticals financials, year by year
Annual reports27
- Annual report, year to Mar 2025 (opens in a new tab)8 Sep 2025
- Annual report, year to Mar 2024 (opens in a new tab)8 Sep 2024
- Annual report, year to Mar 2023 (opens in a new tab)7 Sep 2023
- Annual report, year to Mar 2022 (opens in a new tab)7 Sep 2022
- Annual report, year to Mar 2021 (opens in a new tab)2 Sep 2021
22 earlier reports
- Annual report, year to Mar 2020 (opens in a new tab)8 Dec 2020
- Annual report, year to Mar 2019 (opens in a new tab)26 Aug 2019
- Annual report, year to Mar 2018 (opens in a new tab)18 Aug 2018
- Annual report, year to Mar 2017 (opens in a new tab)12 Oct 2017
- Annual report, year to Mar 2016 (opens in a new tab)14 Oct 2016
- Annual report, year to Mar 2015 (opens in a new tab)15 Aug 2015
- Annual report, year to Mar 2014 (opens in a new tab)18 Aug 2014
- Annual report, year to Mar 2013 (opens in a new tab)3 Oct 2013
- Annual report, year to Mar 2012 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2011 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2010 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2009 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2008 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2007 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2006 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2005 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2004 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2003 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2002 (opens in a new tab)Filing day not known
- Annual report, year to Mar 2000 (opens in a new tab)Filing day not known
- Annual report, year to Mar 1999 (opens in a new tab)Filing day not known
- Annual report, year to Mar 1998 (opens in a new tab)Filing day not known
Investor presentations1
Vista Pharmaceuticals share news and announcements
532 announcements, routine notices left out, newest first. Page 1 of 11.
Sep 2026
12 Sep · Management
Aug 2026
14 Aug · Results
14 Aug · Results
13 Aug · Board meeting
Meeting on 14 Aug 2026: quarterly results
May 2026
29 May · Results
19 May · Board meeting
Meeting on 29 May 2026: audited results
Apr 2026
29 Apr · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Feb 2026
13 Feb · Results
5 Feb · Board meeting
Meeting on 13 Feb 2026: quarterly results3 Feb · Business
Nov 2025
4 Nov · Board meeting
Meeting on 13 Nov 2025: quarterly results
Sep 2025
30 Sep · Meeting
Aug 2025
6 Aug · Board meeting
Meeting on 13 Aug 2025: quarterly results
Jul 2025
16 Jul · Outcome Of Circular Resolution Passed By Board Of Directors Of The Company By Circulation On July 16, 2025 Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
Jun 2025
27 Jun · Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements Requirements) Regulations, 2015.
May 2025
30 May · Board meeting
20 May · Board meeting
Meeting on 30 May 2025: audited results
Apr 2025
30 Apr · Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
Mar 2025
Feb 2025
14 Feb · Board meeting
Meeting on 19 Feb 2025: increase in authorised capital and preferential issue of shares3 Feb · Board meeting
Meeting on 12 Feb 2025: quarterly results
Nov 2024
14 Nov · Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 - 'Issue Of World Health Organisation (WHO) G.M.P. Certificate.
How the price met the news
The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.
- 15 Sep 2026Board or managers changedup 0.35%+2.0 pts vs Nifty 500market median 0.0% · five sessions −2.8% (−2.8 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 17 Oct 2023Board or managers changedup 3.72%+3.3 pts vs Nifty 500market median 0.0% · five sessions −0.9% (+2.0 pts vs Nifty 500) · volume 0.4× usual · The announcement (opens in a new tab)
- 19 Jun 2023Board or managers changeddown 0.89%−0.6 pts vs Nifty 500market median 0.0% · five sessions +3.6% (+4.6 pts vs Nifty 500) · volume 0.3× usual · The announcement (opens in a new tab)
- 12 Sep 2022Board or managers changeddown 2.99%−3.7 pts vs Nifty 500market median 0.0% · five sessions −4.3% (−2.9 pts vs Nifty 500) · volume 0.4× usual · The announcement (opens in a new tab)
- 27 Jun 2022Board or managers changeddown 0.71%−1.6 pts vs Nifty 500market median 0.0% · five sessions −0.3% (−0.8 pts vs Nifty 500) · volume 0.6× usual · The announcement (opens in a new tab)
- 1 Apr 2021Board or managers changedup 3.10%+1.8 pts vs Nifty 500market median 0.0% · five sessions +10.7% (+8.9 pts vs Nifty 500) · volume 0.2× usual · The announcement (opens in a new tab)
- 13 Nov 2020Board or managers changeddown 0.60%−1.0 pts vs Nifty 500market median 0.0% · five sessions −3.1% (−4.4 pts vs Nifty 500) · volume 1.7× usual · The announcement (opens in a new tab)
- 19 Aug 2020Board or managers changeddown 4.81%−5.1 pts vs Nifty 500market median 0.0% · five sessions −0.6% (−2.0 pts vs Nifty 500) · volume 2.3× usual · The announcement (opens in a new tab)
- 8 Aug 2016Board or managers changedup 4.41%+3.9 pts vs Nifty 500market median 0.0% · five sessions +3.5% (+3.7 pts vs Nifty 500) · volume 0.6× usual · The announcement (opens in a new tab)
Figures filed again
Lines the company later filed with a different value, rupee lines in ₹ crore and per-share lines in rupees.
| Line | Period | Accounts | First filed | Filed again | Change. The value filed again less the value first filed, as a per cent of the first. | First filed on | Filed again on |
|---|---|---|---|---|---|---|---|
| Depreciation and amortisation | Quarter to Jun 2020 | Standalone | 0.17 | 0.17 | −0.1% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Total expenses | Quarter to Jun 2020 | Standalone | 0.90 | 0.90 | 0.0% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Profit before tax | Quarter to Jun 2020 | Standalone | −0.90 | −0.90 | 0.0% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Tax | Quarter to Jun 2020 | Standalone | −0.56 | 0.56 | +200.0% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Net profit | Quarter to Jun 2020 | Standalone | −0.34 | −1.46 | −335.8% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Profit before one-off items and tax | Quarter to Jun 2020 | Standalone | −0.90 | −0.90 | 0.0% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Deferred tax | Quarter to Jun 2020 | Standalone | −0.56 | 0.56 | +200.0% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Net profit from continuing businesses | Quarter to Jun 2020 | Standalone | −0.34 | −1.46 | −335.8% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |
| Total comprehensive income | Quarter to Jun 2020 | Standalone | −0.34 | −1.46 | −335.8% | 14 Sep 2020 (opens in a new tab) | 17 Nov 2020 (opens in a new tab) |